Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kabashima

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1988
The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled studyT Matsunaga, S Ohyama, S Takehara, et al.
The British Journal of Dermatology|September 30, 2009
Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitisT Mori, K Ishida, S Mukumoto, et al.
Mucosal Immunology|August 3, 2017
Regulatory T cells with superior immunosuppressive capacity emigrate from the inflamed colon to draining lymph nodesY Nakanishi, R Ikebuchi, T Chtanova, et al.
Allergy|June 13, 2017
What's in a name? Atopic dermatitis or atopic eczema, but not eczema aloneJ I Silverberg, J P Thyssen, A S Paller, et al.
The British Journal of Dermatology|December 29, 2016
Three-dimensional evaluation of subclinical extension of extramammary Paget disease: visualization of the histological border and its comparison to the clinical borderT Murata, T Honda, G Egawa, et al.
The British Journal of Dermatology|September 30, 2019
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trialsN Katoh, Y Kataoka, H Saeki, et al.
The British Journal of Dermatology|September 27, 2015
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled studyO Nemoto, M Furue, H Nakagawa, et al.
Science (New York, N.Y.)|March 17, 2000
Prostaglandin D2 as a mediator of allergic asthmaT Matsuoka, M Hirata, H Tanaka, et al.
Experimental Dermatology|September 28, 2006
Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?J M Schröder, K Reich, K Kabashima, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1988
The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled studyT Matsunaga, S Ohyama, S Takehara, et al.
The British Journal of Dermatology|September 30, 2009
Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitisT Mori, K Ishida, S Mukumoto, et al.
Mucosal Immunology|August 3, 2017
Regulatory T cells with superior immunosuppressive capacity emigrate from the inflamed colon to draining lymph nodesY Nakanishi, R Ikebuchi, T Chtanova, et al.
Allergy|June 13, 2017
What's in a name? Atopic dermatitis or atopic eczema, but not eczema aloneJ I Silverberg, J P Thyssen, A S Paller, et al.
The British Journal of Dermatology|December 29, 2016
Three-dimensional evaluation of subclinical extension of extramammary Paget disease: visualization of the histological border and its comparison to the clinical borderT Murata, T Honda, G Egawa, et al.
The British Journal of Dermatology|September 30, 2019
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trialsN Katoh, Y Kataoka, H Saeki, et al.
The British Journal of Dermatology|September 27, 2015
The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled studyO Nemoto, M Furue, H Nakagawa, et al.
Science (New York, N.Y.)|March 17, 2000
Prostaglandin D2 as a mediator of allergic asthmaT Matsuoka, M Hirata, H Tanaka, et al.
Experimental Dermatology|September 28, 2006
Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?J M Schröder, K Reich, K Kabashima, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2023
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristicsJ P Thyssen, D Thaçi, T Bieber, et al.
Pageof 4